{"id":"W4410463909","doi":"10.1016/j.esmoop.2025.104766","title":"212P Cost-effectiveness analysis of ribociclib plus endocrine therapy (ET) versus ET alone in the adjuvant treatment of stage II and III pre and postmenopausal women with HR+/HER2− early breast cancer (EBC): A Canadian payer perspective","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Novartis (Canada); Mount Sinai Hospital","funders":"Daiichi Sankyo Europe; Ipsen; Eisai; Pfizer; Ministero della Salute; Incyte; Teva Pharmaceutical Industries; Gilead Sciences; Amgen; Associazione Italiana per la Ricerca sul Cancro; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Stage (stratigraphy); Oncology; Internal medicine; Gynecology; Postmenopausal women; Adjuvant; Breast cancer; Cancer; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002782478,0.0002591412,0.0008693758,0.0003281701,0.00009273813,0.00003103957,0.000164562,0.00004564998,0.00009814999],"category_scores_gemma":[0.000009990086,0.0001620658,0.00003850246,0.0008149286,0.0002190603,0.0001959604,0.00007237988,0.0001282163,1.032512e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001267776,"about_ca_system_score_gemma":0.0008845988,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.6976329,"about_ca_topic_score_gemma":0.5165538,"domain_scores_codex":[0.9986141,0.0002344857,0.0002212619,0.0004101077,0.000196007,0.0003239828],"domain_scores_gemma":[0.9989702,0.0002216855,0.000130961,0.0003676896,0.0001824506,0.0001270268],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1865342,0.002100055,0.4451496,0.0001970194,0.02676371,0.0003916846,0.2084248,0.001797881,0.003752216,0.006417299,0.00001162395,0.1184599],"study_design_scores_gemma":[0.02380274,0.0038875,0.9612086,0.0001621667,0.0005816974,0.0000167616,0.008717361,0.00004679121,0.0007336548,0.00005362201,0.0006372079,0.000151858],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914467,0.002055831,0.00001524609,0.002407728,0.0000263228,0.002690295,0.0005678561,0.000008160675,0.0007818536],"genre_scores_gemma":[0.9972157,0.0009885372,0.00006694915,0.0003092376,0.00001134581,0.0009735614,0.00002855127,0.00002230707,0.0003837628],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.516059,"threshold_uncertainty_score":0.6608852,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02366314475686798,"score_gpt":0.3695961573708598,"score_spread":0.3459330126139918,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}